Search | Clinical Trials Finder

Conditions: Dermatitis, Atopic
Interventions: Buccal Swab; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 6 Months to 5 Years
Enrollment: 751 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 7
States / cities: Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 4 more

Conditions: ALLERGIC RHINITIS
Interventions: dust mite extract or placebo; Biological
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: MEDI-573, Aromatase Inhibitor; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 34
States / cities: Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration; Other
Lead sponsor: Arkansas Heart Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Atopic Dermatitis
Interventions: Galvokimig, Placebo; Biological · Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Oceanside, California • Santa Monica, California • Boca Raton, Florida + 14 more

Conditions: Atopic Dermatitis
Interventions: Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream; Drug · Device
Lead sponsor: Ceragenix Pharmaceuticals; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: San Diego, California • Portland, Oregon

Conditions: Atopic Dermatitis
Interventions: ATI-502; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Encinitas, California • San Diego, California • Fridley, Minnesota + 3 more

Conditions: Atopic Dermatitis
Interventions: 0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions: XmAb7195, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Toxic Epidermal Necrolysis
Interventions: Clobetasol 0.05% ointment, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 7 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Psoriasis, Atopic Dermatitis
Interventions: XmAb27564, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Sherman Oaks, California • Thousand Oaks, California • Coral Gables, Florida + 3 more

Conditions: Atopic Dermatitis
Interventions: GHZ339, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions: ENS-002; Biological
Lead sponsor: Concerto Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Hollywood, Florida • Beverly, Massachusetts • Austin, Texas

Conditions: Dermatitis, Atopic
Interventions: P3-Fast, Comm-Fast, Vari-Fast, Comm-Fed; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Eczema, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: TopMD Skin Care, Inc.; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, JNJ-95475939, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more

Conditions: Atopic Dermatitis
Interventions: Roseomonas mucosa; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 29
States / cities: Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more

Conditions: Atopic Dermatitis, Vitamin D Deficiency
Interventions: Vitamin D; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Dermatitis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Search by objective public record fields.

Histamine Pharmacogenetics in Children With Atopic Dermatitis

Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Topical ENS-002 for Atopic Dermatitis in Adults

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Vitamin D Deficiency and Atopic Dermatitis

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)